The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids
Abstract
Mitochondrila DNA (mtDNA) is the only extrachromosomal DNA in humans. It is a small (16.5 kb) genome which encodes 13 essential peptides of the respiratory chain, two rRNAs and 22 tRNAs. Defects of this genome are now recognized as important causes of disease and may take the form of point mutations or rearrangements. There is no effective treatment for patients with mtDNA mutations. In the majority of patients with mtDNA defects, both mutant and wild-type molecules are present in the same cell-a phenomenon known as intracellular heteroplasmy. In addition, in the presence of heteroplasmy there is a threshold whereby a certain level of mutant mtDNA is necessary before the disease becomes biochemically and clinically apparent. Based on the presence of heteroplasmy and the recessive nature of these mutations, we believe it will be possible to treat patients by selectively inhibiting the replication of the mutant mtDNA, thereby allowing propagation of only the wild-type molecule. To confirm the validity of such an approach we synthesised peptide nucleic acids (PNAs) complementary to human mtDNA templates containing a deletion breakpoint or single base mutation, both mutations well documented to cause disease. Using an in vitro replication run-off assay under physiological conditions, the antigenomic PNAs specifically inhibited replication of mutant but not wild-type mtDNA templates. Furthermore, we have shown uptake of these PNAs into cultured human myoblasts. We believe that we have therefore established the potential value of antigenomic PNA therapy for patients with heteroplasmic mtDNA disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antigenomic therapy, which involves using sequence-specific nucleic acid derivatives that selectively target and inhibit the replication of mutated mtDNA thus allowing the wild-type genome to propagate, showed promising initial results in vitro with peptide nucleic acids (PNAs) [234].”
From Mitochondrial DNA mutations and human disease (2010) · cites this paper as [234]
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Sequence and organization of the human mitochondrial genome
Anderson, S., Bankier, A. T., Barrell, B. G., de Bruijn, M. H. L., Coulson, A. R., Drouin, J., Eperon, I. C., Nierlich, D. P., Roe, B. A., Sanger, F., et al. (1981) · Nature · doi:10.1038/290457a0 · Cited by 9,740
Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide
Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991) · Science · doi:10.1126/science.1962210 · Cited by 3,332
PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen-bonding rules
Egholm, M., Buchardt, O., Christensen, L., Behrens, C., Freier, S. M., Driver, D. A., Berg, R. H., Kim, S. K., Norden, B., & Nielsen, P. E. (1993) · Nature · doi:10.1038/365566a0 · Cited by 2,079
Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies
Holt, I. J., Harding, A. E., & MORGAN-HUGHES, J. A. (1988) · Nature · doi:10.1038/331717a0 · Cited by 1,860
Shoffner, J. M., Lott, M. T., Lezza, A. M. S., Seibel, P., Ballinger, S. W., & Wallace, D. C. (1990) · Cell · doi:10.1016/0092-8674(90)90059-n · Cited by 1,476
Diseases of the mitochondrial DNA
Wallace, D. C. (1992) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.61.070192.005523 · Cited by 1,319
Mitochondrial Genetics: A Paradigm for Aging and Degenerative Diseases?
Wallace, D. C. (1992) · Science · doi:10.1126/science.1533953 · Cited by 1,262
Mitochondrial DNA Deletions in Progressive External Ophthalmoplegia and Kearns-Sayre Syndrome
Moraes, C. T., DiMauro, S., Zeviani, M., Lombès, A., Shanske, S., Miranda, A. F., Nakase, H., Bonilla, E., Werneck, L. C., Servidei, S., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198905183202001 · Cited by 1,029
Stability of peptide nucleic acids in human serum and cellular extracts
Demidov, V. V., Potaman, V. N., Frank-Kamenetskii, M. D., Egholm, M., Buchard, O., Sönnichsen, S. H., & Nlelsen, P. E. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90171-6 · Cited by 749
Cited by
Sorted by citations
Items 201–248 of 248
Targeting the Mitochondria in Cardiovascular Diseases
Marı́n-Garcı́a, J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4599-9_23 · Cited by 1
Mitochondrial Energy Metabolism
Boelen, C. C. A., & Smeitink, J. A. M. (2006) · Springer eBooks · doi:10.1007/3-540-28962-3_29 · Cited by 1
Chapter 7 Current and Future Prospects for the Treatment of Mitochondrial Disorders
Taylor, R. W., & Turnbull, D. M. (2002) · Blue books of practical neurology · doi:10.1016/s1877-3419(09)70066-2 · Cited by 1
PNAs breach the blood-brain barrier?
During, M. J., & Janson, C. G. (1999) · Nature Biotechnology · doi:10.1038/11684 · Cited by 1
Mitochondrial Heteroplasmy and Disease
Elson, J. L., & Lightowlers, R. N. (2006) · Encyclopedia of Life Sciences · doi:10.1038/npg.els.0006079 · Cited by 1
Mitochondrial DNA mutations in the haematopoietic system
Taylor, R. W., He, L., Proctor, S., Middleton, P. G., & Turnbull, D. M. (2003) · Leukemia · doi:10.1038/sj.leu.2403208 · Cited by 1
Genetic Basis of Mitochondrial Disease
Johns, D. R. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-726-0_103 · Cited by 1
Peptide nucleic acids as agents to modify target gene expression and function
Wang, G., & Glazer, P. M. (2003) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-004-4903-0 · Cited by 1
Sokol, R. J. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511547409.035 · Cited by 1
Mitochondrial Encephalomyopathies
DiMauro, S., Mancuso, M., & Naini, A. (2004) · Springer eBooks · doi:10.1007/978-3-662-41088-2_23 · Cited by 1
Mitochondrial dysfunction in diabetes mellitus
Anderson, C. M. (1999) · Drug Development Research · doi:10.1002/(sici)1098-2299(199901)46:1 · Cited by 18
HAMOWANIE WZROSTU BAKTERII PRZEZ PEPTYDOWE KWASY NUKLEINOWE I ICH POTENCJALNA ROLA W BIOTECHNOLOGII
Markowska‐Zagrajek, A., Równicki, M., & Trylska, J. (2014) · Postępy Mikrobiologii - Advancements of Microbiology
Myopathies: Ethics, Outcome Variables and Clinical Scales
Orrell, R. W., & Guiloff, R. J. (2001) · Springer eBooks · doi:10.1007/978-1-4471-3787-0_40
Uptake Pathways Dependent Intracellular Trafficking of DNA Carrying Nanodelivery Systems
Khalil, I. A., Yamada, Y., Akita, H., & Harashima, H. (2010) · doi:10.1002/9780470875780.ch25
Models of mitochondrial disease
Liolitsa, D., & Hanna, M. G. (2002) · International review of neurobiology · doi:10.1016/s0074-7742(02)53016-6
Eriksson, M. (2002) · Wiley Encyclopedia of Molecular Medicine · doi:10.1002/0471203076.emm0201
Elle, J. S. (2005) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.3766
Mitochondrial dysfunction in hereditary optic neuropathies
Casalena, G. (2009) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.6092/unibo/amsdottorato/1557
The use of PNAs and their derivatives in mitochondrial gene therapy
Smith, P., Ross, G. F., Wardell, T. M., Taylor, R. W., Turnbull, D. M., & Lightowlers, R. N. (2003) · International Journal of Peptide Research and Therapeutics · doi:10.1007/bf02484570 · Cited by 1
PNAs as Novel Cancer Therapeutics
Mologni, L., & Gambacorti-Passerini, C. B. (2007) · Springer eBooks · doi:10.1007/0-387-32956-0_11
Modulation of Nucleic Acid Information Processing by PNAs
Bastide, L., Lebleu, B., & Robbins, I. J. (2007) · Springer eBooks · doi:10.1007/0-387-32956-0_2
BACTERIAL GENE EXPRESSION INHIBITION WITH ANTISENSE PEPTIDE NUCLEIC ACIDS
Dryselius, R. (2005) · Figshare
MITOCHONDRIAL CYTOPATHIES IN CHILDREN AND ADULTS
Tarnopolsky, M. A. (2009) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000348880.16694.08
Selective Inhibition of Mutant Mitochondrial DNA Replication
Taylor, R. W., Chinnery, P. F., Clark, K. M., Lightowlers, R. N., & Turnbull, D. M. (1997) · Emerging Therapeutic Targets · doi:10.1517/14728222.1.1.249
A model for mitochondrial disease associated with rearrangements of the mitochondrial genome
Glasssmith, L. L. (1998) · Enlighten: Theses (The University of Glasgow)
PNAs as novel cancer therapeutics
Mologni, L., & Gambacorti-Passerini, C. B. (2003) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-004-4909-7
“Taylor and coworkers have blocked mutant mitochondrial (mt) DNA replication selectively, suggesting that PNA may be used to correct heteroplasmy of mtDNA [70].”
BackgroundNagasaki, T., & Hamada, T. (2017) · The Review of Laser Engineering · doi:10.2184/lsj.45.11_696
Hidaka, T. (2022) · Springer theses · doi:10.1007/978-981-16-8436-4_1
Hidaka, T. (2022) · Springer theses · doi:10.1007/978-981-16-8436-4_3
Treatment of Mitochondrial-Based Cardiac Diseases. Targeting the Organelle
Marı́n-Garcı́a, J. (2005) · Developments in cardiovascular medicine · doi:10.1007/0-387-25575-3_11
PNAs as novel cancer therapeutics
Mologni, L., & Gambacorti-Passerini, C. B. (2005) · Letters in Peptide Science · doi:10.1007/s10989-005-4909-2
Viscomi, C. F., & Zeviani, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-05517-2_22
Medicinal Chemistry of Plasmid DNA with Peptide Nucleic Acids
Zelphati, O., Felgner, J. H., Wang, Y., Liang, X., Wang, X., & Felgner, P. L. (2007) · Springer eBooks · doi:10.1007/0-387-32956-0_12
The Use of PNAs and Their Derivatives in Mitochondrial Gene Therapy
Smith, P., Ross, G. F., Wardell, T. M., Taylor, R. W., Turnbull, D. M., & Lightowlers, R. N. (2007) · Springer eBooks · doi:10.1007/0-387-32956-0_16
Medicinal chemistry of plasmid DNA with peptide nucleic acids: A new strategy for gene therapy
Zelphati, O., Felgner, J. H., Wang, Y., Liang, X., & Felgner, P. L. (2005) · Letters in Peptide Science · doi:10.1007/s10989-005-4907-4
Peptide nucleic acids as agents to modify target gene expression and function
Gan, W., & Glazer, P. M. (2005) · Letters in Peptide Science · doi:10.1007/s10989-005-4903-8
The use of PNAs and their derivatives in mitochondrial gene therapy
Smith, P., Ross, G. F., Wardell, T. M., Taylor, R. W., Turnbull, D. M., & Lightowlers, R. N. (2005) · Letters in Peptide Science · doi:10.1007/s10989-005-4901-x
Modulation of nucleic acid information processing by PNAs: potential use in anti-viral therapeutics
Bastide, L., Lebleu, B., & Robbins, I. J. (2003) · International Journal of Peptide Research and Therapeutics · doi:10.1007/bf02484556
Peptide nucleic acids as agents to modify target gene expression and function
Gan, W., & Glazer, P. M. (2003) · International Journal of Peptide Research and Therapeutics · doi:10.1007/bf02484568
Modulation of nucleic acid information processing by PNAs: Potential use in anti-viral therapeutics
Bastide, L., Lebleu, B., & Robbins, I. J. (2005) · Letters in Peptide Science · doi:10.1007/s10989-005-4923-4
Medicinal chemistry of plasmid DNA with peptide nucleic acids: A new strategy for gene therapy
Zelphati, O., Felgner, J. H., Wang, Y., Liang, X., Wang, X., & Felgner, P. L. (2003) · International Journal of Peptide Research and Therapeutics · doi:10.1007/bf02484566
Sperl, W., & Freisinger, P. (2008) · Springer eBooks · doi:10.1007/978-3-540-71899-4_18
Yao, L., & Zhang, T. (2024) · Wiley eBooks · doi:10.1002/9783527841912.ch4
Gene Therapy of Mitochondrial DNA Diseases
Seibel, P., Flierl, A., Bachmann, C., & Seibel, M. (1998) · Springer eBooks · doi:10.1007/978-3-662-12509-0_20
Jeandard, D. (2019) · theses.fr (ABES) · doi:10.70675/292f625az9431z45aaz8426z08c82f3bffa3
Future Frontiers in Heart Failure
Marı́n-Garcı́a, J. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-147-9_23
Metadata
- Authors
- Taylor, R. W., Chinnery, P. F., Turnbull, D. M., & Lightowlers, R. N.
- Affiliations
- Newcastle University (GB)
- Corresponding author
- Turnbull, Douglass M.
- Venue
- Nature Genetics
- Published
- 1997-02
- Volume
- 15
- Issue
- 2
- Pages
- 212-215
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1964789697
- Cited by
- 249
- References
- 31
- Citations by year
- 2025: 5 · 2024: 2 · 2023: 3 · 2022: 4 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 9 · 2017: 2 · 2016: 6 · 2015: 8 · 2014: 6 · 2013: 2 · 2012: 10
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- mitochondrial DNA, mitochondrial DNA replication, peptide nucleic acid, heteroplasmy, myoblasts, mitochondrial disease, deletion breakpoints, single-base mutations
- MeSH terms
- Cell Line, Depression, Chemical, DNA Replication, DNA, Mitochondrial, DNA, Single-Stranded, Humans, Mitochondria, Muscle, Oligodeoxyribonucleotides, Peptides, Templates, Genetic, Drug Design, MERRF Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
